Co-Diagnostics, Inc. (CODX)
Total Valuation
Co-Diagnostics has a market cap or net worth of $34.70 million. The enterprise value is -$20.86 million.
Market Cap | 34.70M |
Enterprise Value | -20.86M |
Important Dates
The last earnings date was Thursday, March 14, 2024, after market close.
Earnings Date | Mar 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 31.26 million shares outstanding. The number of shares has decreased by -6.77% in one year.
Shares Outstanding | 31.26M |
Shares Change (YoY) | -6.77% |
Shares Change (QoQ) | +0.36% |
Owned by Insiders (%) | 2.68% |
Owned by Institutions (%) | 15.79% |
Float | 30.41M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 16.00 |
PS Ratio | 5.09 |
Forward PS | 5.87 |
PB Ratio | 0.40 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.81, with a Debt / Equity ratio of 0.03.
Current Ratio | 10.81 |
Quick Ratio | 10.24 |
Debt / Equity | 0.03 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -35.40% and return on invested capital (ROIC) is -47.98%.
Return on Equity (ROE) | -35.40% |
Return on Assets (ROA) | -32.60% |
Return on Capital (ROIC) | -47.98% |
Revenue Per Employee | $43,949 |
Profits Per Employee | -$227,954 |
Employee Count | 155 |
Asset Turnover | 0.06 |
Inventory Turnover | 1.20 |
Taxes
Income Tax | -2.78M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.42% in the last 52 weeks. The beta is -0.70, so Co-Diagnostics's price volatility has been lower than the market average.
Beta (1Y) | -0.70 |
52-Week Price Change | -19.42% |
50-Day Moving Average | 1.17 |
200-Day Moving Average | 1.21 |
Relative Strength Index (RSI) | 46.58 |
Average Volume (30 Days) | 70,136 |
Short Selling Information
The latest short interest is 381,538, so 1.22% of the outstanding shares have been sold short.
Short Interest | 381,538 |
Short Previous Month | 341,333 |
Short % of Shares Out | 1.22% |
Short % of Float | 1.25% |
Short Ratio (days to cover) | 6.76 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $6.81 million and -$35.33 million in losses. Loss per share was -$1.20.
Revenue | 6.81M |
Gross Profit | 2.63M |
Operating Income | -42.71M |
Pretax Income | -38.11M |
Net Income | -35.33M |
EBITDA | -36.83M |
EBIT | -38.11M |
Loss Per Share | -$1.20 |
Balance Sheet
The company has $58.55 million in cash and $2.99 million in debt, giving a net cash position of $55.56 million or $1.78 per share.
Cash & Cash Equivalents | 58.55M |
Total Debt | 2.99M |
Net Cash | 55.56M |
Net Cash Per Share | $1.78 |
Equity / Book Value | 86.01M |
Book Value Per Share | 2.75 |
Working Capital | 56.39M |
Cash Flow
In the last 12 months, operating cash flow was -$22.08 million and capital expenditures -$1.37 million, giving a free cash flow of -$23.45 million.
Operating Cash Flow | -22.08M |
Capital Expenditures | -1.37M |
Free Cash Flow | -23.45M |
FCF Per Share | -$0.80 |
Margins
Gross margin is 38.57%, with operating and profit margins of -626.92% and -518.68%.
Gross Margin | 38.57% |
Operating Margin | -626.92% |
Pretax Margin | -559.46% |
Profit Margin | -518.68% |
EBITDA Margin | -540.69% |
EBIT Margin | -559.46% |
FCF Margin | -344.20% |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 6.77% |
Shareholder Yield | 6.77% |
Earnings Yield | -101.83% |
FCF Yield | -67.57% |
Analyst Forecast
The average price target for Co-Diagnostics is $2.50, which is 123.21% higher than the current price. The consensus rating is "Hold".
Price Target | $2.50 |
Price Target Difference | 123.21% |
Analyst Consensus | Hold |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of 1.77 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.77 |
Piotroski F-Score | 2 |